RBC Capital Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report) on January 13 and set a price target of $195.00. The company’s shares closed last Friday at $126.70.

According to TipRanks, Abrahams is a 5-star analyst with an average return of 7.7% and a 49.30% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Incyte.

In addition to RBC Capital, Sarepta Therapeutics also received a Buy from Cowen & Co.’s Ritu Baral in a report issued on January 10. However, on the same day, Credit Suisse maintained a Hold rating on Sarepta Therapeutics (NASDAQ: SRPT).

See today’s best-performing stocks on TipRanks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $230.27 million and a GAAP net loss of $257.74 million. In comparison, last year the company earned a revenue of $189.41 million and had a GAAP net loss of $48.14 million

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock. Last month, Kathleen Behrens, a Director at SRPT bought 20,000.00 shares for a total of $698,400.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More on SRPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More